The airport's Jeff Beck three-year capital plan is estimated

The airport's determines Jeff Beck three-year capital jeff beck "love is blue spells out plan is estimated to cost $84 million andprimarily focuses on alleviating current parking constraints through debtfinancing. Major funding sources for the airport include AIP funding and futurebond issuances, which will fund 40% and 56% of the plan, respectively. Theairport completed parking projects in 2003 and added approximately 900 newgarage parking spaces, but management currently estimates that during peakperiods approximately 1,400 vehicles are parked in overflow lots and areas dueto a shortage of parking spaces. Current terminal and airfield facilities areestimated to adequately meet passenger demand through 2013 and management doesnot anticipate additional capacity expansion during that period. Of the $84million CIP planned, the airport estimates the new parking garage and associatedoutlays will cost approximately $46 million and will be funded entirely throughfuture bond issuances. Although airport management has conveyed the flexibilityto stagger and possibly scale back some of the parking garage development,particularly the environmentally-friendly elements of the proposed design, thecurrent parking constraints at the airport will require management to act in thenear term.

However, should the airport double its debt burden and issuerevenue-supported bonds for the entire estimated project costs, the airportwould be substantially overleveraged and its financial flexibility would beseverely impaired jeff beck wired . Burlington International Airport (BTV) is classified by the Federal AviationAdministration (FAA) as a small hub airport and is located 4 miles from downtownBurlington, yet draws from a customer base in Vermont, New Hampshire, New Yorkand parts of Canada jeef beck . BTV's facilities include two intersecting runways, an115,000-square-foot terminal building, and 2,078 garage parking spaces and 1,500surface parking spaces jeff beck "you know what i mean . Fitch's rating definitions and the terms of use of such ratings are available onthe agency's public site, Published ratings, criteria andmethodologies are available from this site, at all times clapton beck . Fitch's code ofconduct, confidentiality, conflicts of interest, affiliate firewall, complianceand other relevant policies and procedures are also available from the 'Code ofConduct' section of this site.

Fitch Ratings, New YorkVanessa Roy, +1-212-908-0508Mike McDermott, +1-212-908-0605Cindy Stoller, +1-212-908-0526 (Media Relations)Copyright Business Wire 2009 jeff beck chords . AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial ofSublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in TreatingProcedural Pain and AnxietyResults Show Successful Clinical Validation of Pharmacodynamic EffectREDWOOD CITY, Calif., Jan wired beck . 12 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc., anemerging specialty pharmaceutical company focused on the treatment ofintermittent and acute medical conditions with an initial emphasis on painmanagement, today announced positive results from a Phase 1 clinical studyevaluating the safety, tolerability and efficacy of the company's proprietarysublingual sufentanil (opioid) and triazolam (benzodiazepine) NanoTab(TM)combination product candidate (ARX-03).The product is designed to addressthe current unmet need for a non-invasive product to provide sedation andanalgesia for an increasing number of office-based procedures.The study demonstrated that administration of ARX-03 resulted in astatistically significant increase in sedation levels for the 10mcgsufentanil/200mcg triazolam dosage strength in both a younger cohort (agerange 18-60 years; p=0.009) and an older cohort (age range of 61-80 years;p=0.003) as compared to sublingual sufentanil alone.These data werecollected using the Richmond Agitation-Sedation Scale (RASS), a validated andobjective test for assessment of sedation levels yardbirds beck . The average onset ofsedation was 20-30 minutes for the higher dosage strength in each studycohort.Additionally, sublingual administration of the sufentanil/triazolamcombination was found to be safe and well tolerated guitarist beck . Based on these positiveresults, AcelRx intends to further advance clinical development of ARX-03 in2009."We believe the results of this trial are particularly valuable as they offerclinical evidence well beyond what is expected from a typical Phase 1 study. Not only have we shown ARX-03 to be safe and well-tolerated, we have alsodemonstrated significant pharmacodynamic findings with a randomized,double-blind design that spanned different age groups and multiple dosagelevels," said Pamela Palmer, M.D., Ph.D., chief medical officer of AcelRxPharmaceuticals.

This 24-patient two-cohort, five-arm crossover study included administrationof open-label oral triazolam and IV sufentanil on days one and two followed bya double-blinded, randomized dosing of a sublingual NanoTab(TM) containinghigh-dose sufentanil/triazolam, low-dose sufentanil/triazolam and 10mcgsufentanil only on days three to five jeff beck tablature . ARX-03 is designed to provide analgesia, anxiolysis and mild sedation withoutrequiring the presence of an anesthesiologist, in a safe, simple, non-invasiveform for use in procedural settings.The product is based on the company'sproprietary NanoTab(TM) dosage form, which enables delivery of thesufentanil/triazolam combination by the non-invasive oral transmucosal(sublingual) route, resulting in high drug bioavailability but significantlylower and safer peak plasma levels than IV."The very positive data generated from this study validates the clinicalapplicability of this product concept from both a safety and efficacy point ofview, and further underscores the commitment of AcelRx to advance the clinicaldevelopment of this program," said Thomas A jeff guitarist . Schreck, chairman and chiefexecutive officer of AcelRx Pharmaceuticals crossroads guitar festival . "The positive findings thatAcelRx recently announced regarding our lead product candidate, ARX-01,combined with the impressive data from this ARX-03 study demonstrate thebreadth and value of the AcelRx pipeline and strongly positions the companyfor future success."About ARX-03 Sublingual Sufentanil/Triazolam NanoTab(TM) Combination forProcedural Pain and AnxietyProcedural pain and anxiety in the doctor's office and clinic settingrepresents a significant unmet medical need for patients and healthcareproviders.Most physician's offices and clinics cannot provide appropriatestaffing for IV sedation, often resulting in patients experiencing high levelsof pain and anxiety.Ideal treatment of procedural pain and anxiety minimizespatient awareness and discomfort, while maintaining patient safety.Apreferred product candidate for treatment of procedural pain and anxietyshould possess sedative, analgesic and amnestic properties, be safe, easy touse and administered via a non-invasive route, and have a rapid onset and asufficient duration of action which allows for rapid recovery and discharge eric clapton . AcelRx's novel ARX-03 sublingual NanoTab(TM) is designed to satisfy thesecriteria.

AcelRx is preparing to initiate a Phase 2a clinical trial to further evaluatethe safety and efficacy of ARX-F03 for treatment of procedural pain andanxiety About AcelRx Pharmaceuticals, Inc . AcelRx Pharmaceuticals is a privately held pharmaceutical company dedicated tothe development and commercialization of new therapies for the treatment ofpain and other conditions where there is an unmet need for improved safety andefficacy bootleg beck . The company applies its proprietary dosage form and deliverytechnologies to enhance the safety, therapeutic benefit and commercialattractiveness of currently approved compounds jeff blues . For additional information about AcelRx Pharmaceuticals visit Pharmaceuticals, Inc.Carter King, Vice President, Finance of AcelRx Pharmaceuticals, Inc.,+1-650-216-3500, . On a Wednesday night, Toronto Raptors fans got a glimpse of the potential of their team’s newest rookie.  Playing against the NBA’s current third best rebounding team, the Chicago Bulls, DeMar DeRozan hauled in an impressive nine boards in just 19 minutes.When the Raptors drafted the one year college player from USC, they were drafting potential.  The 6′6.5″ 220 lb freshman was just turning 20 years old and didn’t have the head turning college statistics one might have expected from a NBA lottery pick.In his one season at USC, DeMar averaged 13.9 points, shot 52.3 percent, and collected 5.7 boards, 1.5 assists, 0.9 steals, and 0.4 blocks.  Decent production but perhaps what impressed some of the scouts was the 19.8 point per game average in USC’s five post-season games.But comments about DeRozan have largely revolved around how long and athletic he is.If one looks up DeRozan’s NBA pre-draft camp measurements, they place him squarely in the middle between the average shooting guard and average small forward coming into the league.For an NBA wing player, DeRozan’s height and weight are typical.  His 6’9” wingspan and 8’6.5” standing reach are also average.But what has been most talked about is DeRozan’s great leaping ability.  Some comments suggesting that this is evidenced because he can get his head up to the level of the rim.At pre-draft camp DeRozan’s no step vertical jump was decidedly average at 29”. He did have a maximum vertical jump of 38.5”, which is a couple of inches higher than average but the best leapers in the 2009 draft were at 40″.